Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy

Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyung Sook, Lee, Jae Seob, Lee, Hong Kyung, Park, Eun Jae, Jeon, Hye Won, Kang, Yu Jeong, Lee, Tae Yong, Kim, Kyung Suk, Bae, Sang-Cheol, Park, Ji Hyun, Han, Sang-Bae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829076/
https://www.ncbi.nlm.nih.gov/pubmed/31720047
http://dx.doi.org/10.4110/in.2019.19.e36
Descripción
Sumario:Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and serum creatinine levels in ADR-treated mice. MSCs also prevented podocyte damage and renal fibrosis by decreasing the expression of fibronectin, collagen 1α1, and α-smooth muscle actin. From a mechanistic perspective, MSCs inhibited renal inflammation by lowering the expression of CCL4, CCL7, CCL19, IFN-α/β, TGF-β, TNF-α, and chitinase 3-like 1. In summary, our data demonstrate that MSCs improve renal functions by inhibiting renal inflammation in ADR-induced nephropathy.

Ejemplares similares